A New Light-Activated Treatment for Early Bladder Cancer
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers
This research is developing a new medication that uses light to specifically target and destroy early-stage bladder cancer cells, aiming to reduce recurrence.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11127571 on NIH RePORTER |
What this research studies
Many people with early-stage bladder cancer experience recurrence even after initial surgery and standard treatments like BCG or chemotherapy. Current treatments have limitations, including side effects, high costs, and drug shortages. This project aims to create a new type of drug that becomes active only when exposed to green light, specifically within cancer cells. The goal is to improve how well we treat bladder cancer by precisely targeting cancer cells while leaving healthy bladder tissue unharmed.
Who could benefit from this research
Good fit: This research is focused on patients with non-muscle invasive bladder cancer (NMIBC) who are at high risk for recurrence.
Not a fit: Patients with advanced, muscle-invasive bladder cancer or other types of cancer would likely not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new treatment could offer a more effective way to prevent bladder cancer from returning, with fewer side effects than current options.
How similar studies have performed: This project is exploring a novel concept for light-activated drugs, building on recent internal proof-of-concept work by the researchers.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: You, Youngjae — State University of New York at Buffalo
- Study coordinator: You, Youngjae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.